Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,664 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Dose Drug A Clear all

Conditions: Cancer Of Prostate, Prostate Neoplasms, Prostate Cancer, Neoplasms of Prostate, Prostatic Cancer
Interventions: Prostate bed with integrated boost, Prostate bed irradiation only, Whole Body Bone Scan, 18F-NaF PET Imaging, CT, mpMRI, ADT; Radiation · Diagnostic Test · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation, Fluzone High-Dose vaccine, 2019-2020 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 83 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 2
States / cities: Bardstown, Kentucky • Salt Lake City, Utah

Conditions: Polypoidal Choroidal Vasculopathy
Interventions: ranibizumab 0.5 or 2.0 mg/0.05 cc; Drug
Lead sponsor: Southeast Retina Center, Georgia; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Prostate Cancer
Interventions: Androgen Ablation, Cabazitaxel, Salvage Therapy, Neoadjuvant Treatment - Hormonal Therapy, Neoadjuvant Treatment - Cabazitaxel; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Opioid Use Disorder
Interventions: Psilocybin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Digestive System Disease
Interventions: Low-dose PvP001, Medium-dose PvP001, High-dose PvP001, Placebo; Drug
Lead sponsor: Danielle Kim Turgeon; Other
Eligibility: 18 Years to 64 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Gastrointestinal Discomfort, Digestive Well Being, Gut-related Symptoms
Interventions: Food ingredient of oyster mushroom mycelium (Pleurotus pulmonarius) and microalgae (Chlorella vulgaris); Dietary Supplement
Lead sponsor: Koralo GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Stroke, Transient Ischemic Attack (TIA)
Interventions: CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy); Genetic
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 89 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Peripheral Arterial Disease
Interventions: Ezetimibe, Niaspan, Statin therapy, Standard care, Aspirin, Clopidogrel, Placebo Niaspan, Placebo Ezetimibe, Percutaneous transluminal angioplasty (PTA); Drug · Behavioral · Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 40 Years to 80 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neuralgia, Pain, Peripheral Nervous System Diseases, Herpes Zoster
Interventions: Capsaicin Patch; Drug
Lead sponsor: NeurogesX; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 8
States / cities: Phoenix, Arizona • Tucson, Arizona • Naples, Florida + 5 more

Conditions: Substance-Related Disorders
Interventions: Letters; Other
Lead sponsor: University of Southern California; Other
Eligibility: Not listed
Enrollment: 851 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Diego, California

Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage IV, Head and Neck Cancers - Throat
Interventions: Chemoradiation, Pamiparib, Hydroxyurea, Fluorouracil (5FU), Tislelizumab; Radiation · Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions: Erlotinib; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Food Allergy
Interventions: Egg Oral Immunotherapy, Baked Egg; Drug
Lead sponsor: Hugh A Sampson, MD; Other
Eligibility: 3 Years to 16 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 5
States / cities: Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more

Conditions: Asthma
Interventions: Fp MDPI, Placebo MDPI, Flovent Diskus, albuterol/salbutamol; Drug · Other
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 889 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 148
States / cities: Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 114 more

Conditions: Submental Fat
Interventions: LIPO-202, Placebo for LIPO-202; Drug
Lead sponsor: Neothetics, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 11
States / cities: Beverly Hills, California • Manhattan Beach, California • Greenwood Village, Colorado + 8 more

Conditions: Major Depressive Disorder
Interventions: RX-10100; Drug
Lead sponsor: Rexahn Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 44
States / cities: Cerritos, California • Escondido, California • Los Angeles, California + 38 more

Conditions: Hypoxia, Hypercapnia
Interventions: L-NMMA, Ketorolac, Ascorbic Acid, Intravenous Catheter, Transcranial Doppler Ultrasound; Drug · Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 45 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: Branebrutinib, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Alzheimer Disease, Early Onset
Interventions: Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents, Positron Emission Tomography (PET), Amyvid, MK-6240, Dotarem, Blood draw, UR5e, Urine test; Device · Drug · Other + 2 more
Lead sponsor: Columbia University; Other
Eligibility: 50 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Attention-Deficit Hyperactivity Disorder (ADHD)
Interventions: PDC-1421 Capsule, Placebo; Drug
Lead sponsor: BioLite, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Type 2 Diabetes
Interventions: Routine Care + Glycemic Excursion Minimization (RC+GEM), Routine Care (RC); Behavioral · Other
Lead sponsor: Chiara Fabris, PhD; Other
Eligibility: 30 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Aurora, Colorado • Charlottesville, Virginia

Conditions: Leukemia, Lymphoma, Myeloma, Myeloproliferative Diseases
Interventions: Fludarabine, Melphalan, Alemtuzumab, Stem Cell Infusion, Tacrolimus, Methotrexate, G-CSF, Low Dose Donor T-Cells, High Dose Donor T-Cells; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Rheumatoid Arthritis
Interventions: Cimzia, Magnetic Resonance Imaging (MRI), High-resolution peripheral quantitative computed tomography (HR-pQCT); Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively

Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder

Gastric Gluten-Degradation Activity of PvP001

Evaluation of Gut-Related Well-Being and Mood Effects of a Daily Nutritional Food Ingredient From the Co-Fermentation of Fungal Mycelium (Pleurotus Pulmonarius) and Microalgae (Chlorella Vulgaris)

Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

Pilot Study of High-Dose Capsaicin Patches to Treat Postherpetic Neuralgia Pain

Behavioral Insights to Encourage Judicious Prescribing of Opioids

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma

Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat

Safety and Efficacy of RX-10100 to Treat Major Depressive Disorder

Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation

A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy Participants

Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

PDC-1421 Treatment in Adult Patients With ADHD

Treating Early Type 2 Diabetes by Reducing Postprandial Glucose Excursions: A Paradigm Shift in Lifestyle Modification

Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)

Novel Imaging Markers for Rheumatoid Arthritis